Abstract 2376
Background
Carcinosarcomas are rare tumors that comprise microscopic features of both epithelial tumors (carcinomas) and connective tissue tumors (sarcomas). Data about carcinosarcoma are relatively scarce. In this study, data about carcinosarcoma in the SEER’s database were explored and further analyzed and summarized. SEER incorporates clinical and epidemiological data from 18 cancer registries all over the United States and presented data can be extrapolated to generate evidence on this rarely occurring tumor.
Methods
SEER*Stat Version 8.3.5 was used to obtain data from the SEER 18 Regs Nov 2017 Submission database. Cases diagnosed between 2000-2015 with carcinosarcoma (ICD-O-3 8980/3, 8981/3) were included. Both SEER*Stat and SPSS were used for further data analysis.
Results
A total of 8365 patients were diagnosed with carcinosarcoma between 2000 and 2015, with a median age of 68. The disease occurred predominantly in females (n = 7578; 90.6%) and was more common in white race (n = 6231; 74.5%). Incidence rate was 6.2 per million (CI: 6.1-6.3) with a significant increase of incidence over time (annual percent change = 6.1%) The most common sites for occurrence were the corpus uteri (n = 4656; 55.7%) and ovary (n = 1100; 13.2%) followed by other part of the female genital system (n = 886; 10.6%). The disease was the only primary tumor in 5969 (71.4%) of cases, and the first of 2 or more primaries in 493 patients (8.3%). It occurred as a second or later multiple primary in the remaining percentage of patients (n = 1903; 22.7%). Median survival was 20.5 months, with 5-years and 10-years observed survival being 30.6% (CI: 29.3-31.9%) and 22.4% (CI: 21-23.8%) respectively. Relative survival at 5 years and 10 years was 34.5% (CI: 33.1-36%) and 29.5% (CI: 27.7-31.3%) respectively.
Conclusions
Carcinosarcoma is a rare tumor that occurs with an incidence rate of 6.2 per million. It is predominantly a disease of females who represents 90.6% of cases with female genital system being the main site of occurrence. The disease occurred as a second (or later) primary in 22.7% of patients. It has a median survival of 20.5 months and a relative 5-years survival of 34.5%.
Clinical trial identification
Legal entity responsible for the study
Mohamed Alaa Gouda.
Funding
Has not received any funding.
Editorial Acknowledgement
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
1449 - Prognostic factors associated with pathological complete response in early breast cancer patients undergoing neoadjuvant chemotherapy. The importance of Ki-67 and molecular subtype.
Presenter: Bernardo Rapoport
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4023 - The accuracy of sentinel lymph node biopsy following neoadjuvant chemotherapy in clinically node positive breast cancer patients: A single institution experience
Presenter: Narges Sistany Allahabadi
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4707 - Index BRCA1/2 testing under a multidisciplinary program
Presenter: Duarte Machado
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3393 - BRCA1/BRCA2 germline mutations and chemotherapy-related hematological toxicity in breast cancer patients
Presenter: Alex Friedlaender
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3175 - PALB2 germ-line mutations in Russian breast cancer patients: identification of recurrent alleles and analysis of phenotypic characteristics of the tumors
Presenter: Evgeny Imyanitov
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3027 - Landscape of germline mutations in hereditary breast and ovarian cancer (HBOC) patients in Russia revealed by target panel sequencing
Presenter: Elena Shagimardanova
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4963 - Lynch syndrome-associated hereditary mutations cause breast and ovarian cancer: results from Russian Heredetary Oncogenomics project
Presenter: Marat Gordiev
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2916 - Impact of deleterious germline BRCA mutations, addition of taxanes and use of adjuvant endocrine therapy (ET) on anti-müllerian hormone (AMH) levels in early breast cancer (EBC) patients treated by adjuvant chemotherapy (CT)
Presenter: Nathalie OLYMPIOS
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2400 - Germline mutation status and therapy response in patients with triple-negative breast cancer (TNBC): Results of the GeparOcto study
Presenter: Esther Pohl
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
1345 - BRCA1/BRCA2 Predictive Genetic Testing in an Irish Population: A Missed Opportunity
Presenter: David O Reilly
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract